212 related articles for article (PubMed ID: 19852962)
1. Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients.
Reesink HW; Fanning GC; Farha KA; Weegink C; Van Vliet A; Van 't Klooster G; Lenz O; Aharchi F; Mariën K; Van Remoortere P; de Kock H; Broeckaert F; Meyvisch P; Van Beirendonck E; Simmen K; Verloes R
Gastroenterology; 2010 Mar; 138(3):913-21. PubMed ID: 19852962
[TBL] [Abstract][Full Text] [Related]
2. Rapid viral response of once-daily TMC435 plus pegylated interferon/ribavirin in hepatitis C genotype-1 patients: a randomized trial.
Manns M; Reesink H; Berg T; Dusheiko G; Flisiak R; Marcellin P; Moreno C; Lenz O; Meyvisch P; Peeters M; Sekar V; Simmen K; Verloes R
Antivir Ther; 2011; 16(7):1021-33. PubMed ID: 22024518
[TBL] [Abstract][Full Text] [Related]
3. Rapid decline of viral RNA in chronic hepatitis C patients treated once daily with IDX320: a novel macrocyclic HCV protease inhibitor.
de Bruijne J; van Vliet A; Weegink CJ; Mazur W; Wiercinska-Drapało A; Simon K; Cholewińska-Szymańska G; Kapocsi J; Várkonyi I; Zhou XJ; Temam MF; Molles J; Chen J; Pietropaolo K; McCarville JF; Sullivan-Bólyai JZ; Mayers D; Reesink H
Antivir Ther; 2012; 17(4):633-42. PubMed ID: 22427481
[TBL] [Abstract][Full Text] [Related]
4. Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6: TMC435-C202, a phase IIa, open-label study.
Moreno C; Berg T; Tanwandee T; Thongsawat S; Van Vlierberghe H; Zeuzem S; Lenz O; Peeters M; Sekar V; De Smedt G
J Hepatol; 2012 Jun; 56(6):1247-53. PubMed ID: 22326470
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and antiviral activity of PHX1766, a novel HCV protease inhibitor, using an accelerated Phase I study design.
Hotho DM; de Bruijne J; O'Farrell AM; Boyea T; Li J; Bracken M; Li X; Campbell D; Guler HP; Weegink CJ; Schinkel J; Molenkamp R; van de Wetering de Rooij J; van Vliet A; Janssen HL; de Knegt RJ; Reesink HW
Antivir Ther; 2012; 17(2):365-75. PubMed ID: 22293533
[TBL] [Abstract][Full Text] [Related]
6. Treatment of chronic hepatitis C patients with the NS3/4A protease inhibitor danoprevir (ITMN-191/RG7227) leads to robust reductions in viral RNA: a phase 1b multiple ascending dose study.
Forestier N; Larrey D; Guyader D; Marcellin P; Rouzier R; Patat A; Smith P; Bradford W; Porter S; Blatt L; Seiwert SD; Zeuzem S
J Hepatol; 2011 Jun; 54(6):1130-6. PubMed ID: 21145848
[TBL] [Abstract][Full Text] [Related]
7. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial.
Gane EJ; Roberts SK; Stedman CA; Angus PW; Ritchie B; Elston R; Ipe D; Morcos PN; Baher L; Najera I; Chu T; Lopatin U; Berrey MM; Bradford W; Laughlin M; Shulman NS; Smith PF
Lancet; 2010 Oct; 376(9751):1467-75. PubMed ID: 20951424
[TBL] [Abstract][Full Text] [Related]
8. Virologic response and characterisation of HCV genotype 2-6 in patients receiving TMC435 monotherapy (study TMC435-C202).
Lenz O; Vijgen L; Berke JM; Cummings MD; Fevery B; Peeters M; De Smedt G; Moreno C; Picchio G
J Hepatol; 2013 Mar; 58(3):445-51. PubMed ID: 23142061
[TBL] [Abstract][Full Text] [Related]
9. A Phase I, randomized, placebo-controlled, 3-day, ascending-dose study of GS-9451, an NS3/4A protease inhibitor, in genotype 1 hepatitis C patients.
Lawitz EJ; Hill JM; Marbury T; Demicco MP; Delaney W; Yang J; Moorehead L; Mathias A; Mo H; McHutchison JG; Rodriguez-Torres M; Gordon SC
Antivir Ther; 2013; 18(3):311-9. PubMed ID: 23047118
[TBL] [Abstract][Full Text] [Related]
10. Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection.
Manns MP; Bourlière M; Benhamou Y; Pol S; Bonacini M; Trepo C; Wright D; Berg T; Calleja JL; White PW; Stern JO; Steinmann G; Yong CL; Kukolj G; Scherer J; Boecher WO
J Hepatol; 2011 Jun; 54(6):1114-22. PubMed ID: 21145839
[TBL] [Abstract][Full Text] [Related]
11. Antiviral activity of danoprevir (ITMN-191/RG7227) in combination with pegylated interferon α-2a and ribavirin in patients with hepatitis C.
Forestier N; Larrey D; Marcellin P; Guyader D; Patat A; Rouzier R; Smith PF; Qin X; Lim S; Bradford W; Porter S; Seiwert SD; Zeuzem S
J Infect Dis; 2011 Aug; 204(4):601-8. PubMed ID: 21791662
[TBL] [Abstract][Full Text] [Related]
12. Antiviral activity of boceprevir monotherapy in treatment-naive subjects with chronic hepatitis C genotype 2/3.
Silva MO; Treitel M; Graham DJ; Curry S; Frontera MJ; McMonagle P; Gupta S; Hughes E; Chase R; Lahser F; Barnard RJ; Howe AY; Howe JA
J Hepatol; 2013 Jul; 59(1):31-7. PubMed ID: 23454058
[TBL] [Abstract][Full Text] [Related]
13. Ultra-rapid cardiotoxicity of the hepatitis C virus protease inhibitor BILN 2061 in the urokinase-type plasminogen activator mouse.
Vanwolleghem T; Meuleman P; Libbrecht L; Roskams T; De Vos R; Leroux-Roels G
Gastroenterology; 2007 Oct; 133(4):1144-55. PubMed ID: 17919490
[TBL] [Abstract][Full Text] [Related]
14. Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C.
Reiser M; Hinrichsen H; Benhamou Y; Reesink HW; Wedemeyer H; Avendano C; Riba N; Yong CL; Nehmiz G; Steinmann GG
Hepatology; 2005 Apr; 41(4):832-5. PubMed ID: 15732092
[TBL] [Abstract][Full Text] [Related]
15. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus.
Lamarre D; Anderson PC; Bailey M; Beaulieu P; Bolger G; Bonneau P; Bös M; Cameron DR; Cartier M; Cordingley MG; Faucher AM; Goudreau N; Kawai SH; Kukolj G; Lagacé L; LaPlante SR; Narjes H; Poupart MA; Rancourt J; Sentjens RE; St George R; Simoneau B; Steinmann G; Thibeault D; Tsantrizos YS; Weldon SM; Yong CL; Llinàs-Brunet M
Nature; 2003 Nov; 426(6963):186-9. PubMed ID: 14578911
[TBL] [Abstract][Full Text] [Related]
16. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options.
Suzuki Y; Ikeda K; Suzuki F; Toyota J; Karino Y; Chayama K; Kawakami Y; Ishikawa H; Watanabe H; Hu W; Eley T; McPhee F; Hughes E; Kumada H
J Hepatol; 2013 Apr; 58(4):655-62. PubMed ID: 23183526
[TBL] [Abstract][Full Text] [Related]
17. Antiviral activity of the hepatitis C virus polymerase inhibitor filibuvir in genotype 1-infected patients.
Wagner F; Thompson R; Kantaridis C; Simpson P; Troke PJ; Jagannatha S; Neelakantan S; Purohit VS; Hammond JL
Hepatology; 2011 Jul; 54(1):50-9. PubMed ID: 21488067
[TBL] [Abstract][Full Text] [Related]
18. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study.
Reesink HW; Zeuzem S; Weegink CJ; Forestier N; van Vliet A; van de Wetering de Rooij J; McNair L; Purdy S; Kauffman R; Alam J; Jansen PL
Gastroenterology; 2006 Oct; 131(4):997-1002. PubMed ID: 17030169
[TBL] [Abstract][Full Text] [Related]
19. TMC-435, an NS3/4A protease inhibitor for the treatment of HCV infection.
Tsantrizos YS
Curr Opin Investig Drugs; 2009 Aug; 10(8):871-81. PubMed ID: 19649931
[TBL] [Abstract][Full Text] [Related]
20. Single- and multiple-ascending-dose studies of the NS3 protease inhibitor asunaprevir in subjects with or without chronic hepatitis C.
Pasquinelli C; McPhee F; Eley T; Villegas C; Sandy K; Sheridan P; Persson A; Huang SP; Hernandez D; Sheaffer AK; Scola P; Marbury T; Lawitz E; Goldwater R; Rodriguez-Torres M; Demicco M; Wright D; Charlton M; Kraft WK; Lopez-Talavera JC; Grasela DM
Antimicrob Agents Chemother; 2012 Apr; 56(4):1838-44. PubMed ID: 22290978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
